Search Results 8271-8280 of 33150 for oral

  1. Gelareh Zadeh, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    Best Oral Presentation AwardSociety of British Neurological Surgeons. 2006. PAIRO Resident Teaching AwardResidents and Interns Association of Ontario. 2005.

  2. Salivary gland tumors - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Oral Cavity Cancer and Reconstruction Clinic in Minnesota · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology ...

  3. Leukemia Clinical Trials - Mayo Clinic Research

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  4. A Study to Assess the Effectiveness, Safety and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with Type 2 Inflammation - Mayo Clinic

    ... oral) and/or antibiotics. One of the two required moderate exacerbations has to require the use of systemic corticosteroids. **Severe exacerbations are ...

  5. Holly L. Geyer, M.D. - Doctors and Medical Staff - Mayo Clinic

    Second Runner Up for Oral Presentation in Clinical ResearchMayo Clinic Arizona Academic Excellence Day, Department of Education Administration. 2007.

  6. Robert R. Cima, M.D. - Doctors and Medical Staff - Mayo Clinic

    Associate Board ExaminerOral Boards, American Board of Surgery. 2009 - 2015. Medical Directorinstitution. 2009 - 2012. Executive Committee MemberSurgical and ...

  7. Meet our medical editors - Mayo Clinic

    Ettinger, M.D., D.D.S. — Oral and Maxillofacial Surgeon, Surgical Oncologist; Robert P. Frantz, M.D. — Cardiologist, Internist; Allison E. Garda, M.D. ...

  8. A Study to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly - Mayo Clinic

    Currently receiving other treatments known to affect GH or IGF-1 concentration (including oral estrogens for e.g. contraception or replacement treatment in ...

  9. Intensity-Modulated Radiation Therapy and Paclitaxel with or without Pazopanib Hydrochloride in Treating Patients with Anaplastic Thyroid Cancer - Mayo Clinic

    Patients with any condition that may impair the ability to absorb oral medications/investigational product including: Prior surgical procedures affecting ...

  10. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

    Immunosuppressive or immunomodulating treatment, including chronic oral or IV steroids, must be discontinued at least 4 weeks prior to screening. History of ...